patiromer calcium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5056	1415477-49-4

Description:

Molecule	Description
Synonyms: patiromer calcium patiromer sorbitex calcium veltassa RLY5016S patiromer RLY5016 patiromer glucitol calcium	binds potassium ions in the gastrointestinal tract to lower serum potassium levels Molecular weight: Formula: (C34H52CaO16(C2H3)n(C2H2F)m(C2H3)n(C2H3)p(C2H3)p)x CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

patiromer calcium
patiromer sorbitex calcium
veltassa
RLY5016S
patiromer
RLY5016
patiromer glucitol calcium

binds potassium ions in the gastrointestinal tract to lower serum potassium levels

Molecular weight:
Formula: (C34H52CaO16(C2H3)n(C2H2F)m(C2H3)n(C2H3)p(C2H3)p)x
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
8.40	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 19, 2017	EMA	VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
Oct. 21, 2015	FDA	RELYPSA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	630.92	40.70	364	4109	374017	63110532
Hospitalisation	404.31	40.70	169	4304	84912	63399637
Blood potassium increased	268.86	40.70	84	4389	18225	63466324
Constipation	230.49	40.70	161	4312	224782	63259767
Product dose omission issue	190.65	40.70	146	4327	234167	63250382
Loss of employment	170.64	40.70	38	4435	2206	63482343
Product colour issue	132.41	40.70	25	4448	632	63483917
Off label use	117.53	40.70	186	4287	674276	62810273
No adverse event	103.88	40.70	53	4420	41352	63443197
Dialysis	101.10	40.70	35	4438	10392	63474157
Product taste abnormal	98.72	40.70	24	4449	2043	63482506
Hepatic steatosis	96.74	40.70	45	4428	28724	63455825
Diarrhoea	92.48	40.70	173	4300	715193	62769356
Gastric disorder	91.31	40.70	47	4426	37322	63447227
Cardiac failure congestive	86.85	40.70	63	4410	92370	63392179
Inappropriate schedule of product administration	82.42	40.70	64	4409	103901	63380648
Abdominal pain upper	69.70	40.70	79	4394	206365	63278184
Abdominal discomfort	66.04	40.70	96	4377	320789	63163760
Product solubility abnormal	57.02	40.70	13	4460	837	63483712
Flatulence	55.43	40.70	33	4440	34669	63449880
Malaise	53.86	40.70	101	4372	415853	63068696
Product physical issue	45.50	40.70	16	4457	4964	63479585
Nausea	41.70	40.70	143	4330	854328	62630221

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	927.71	40.84	574	3681	397475	34555201
Hospitalisation	539.19	40.84	216	4039	56686	34895990
Constipation	406.45	40.84	234	4021	136748	34815928
Product dose omission issue	287.79	40.84	179	4076	119532	34833144
Blood potassium increased	262.84	40.84	92	4163	16403	34936273
Dialysis	184.12	40.84	64	4191	11144	34941532
Product taste abnormal	114.75	40.84	27	4228	1147	34951529
Off label use	90.94	40.84	173	4082	419351	34533325
Inappropriate schedule of product administration	89.18	40.84	68	4187	62228	34890448
Product colour issue	87.82	40.84	19	4236	549	34952127
Flatulence	83.58	40.84	44	4211	21154	34931522
No adverse event	72.14	40.84	41	4214	22886	34929790
Diarrhoea	68.99	40.84	148	4107	389764	34562912
Abdominal discomfort	61.73	40.84	54	4201	59781	34892895
Product solubility abnormal	61.70	40.84	14	4241	505	34952171
Product physical issue	59.59	40.84	19	4236	2522	34950154
Treatment noncompliance	49.93	40.84	35	4220	28065	34924611
Abdominal pain upper	41.15	40.84	47	4208	71443	34881233

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	1014.77	40.62	603	5925	565911	79171949
Hospitalisation	478.12	40.62	205	6323	94031	79643829
Constipation	396.16	40.62	260	6268	282790	79455070
Product dose omission issue	367.26	40.62	236	6292	247301	79490559
Blood potassium increased	325.77	40.62	113	6415	29162	79708698
Off label use	174.65	40.62	284	6244	906931	78830929
Loss of employment	159.53	40.62	38	6490	2549	79735311
Abdominal discomfort	127.71	40.62	128	6400	250599	79487261
Dialysis	123.15	40.62	49	6479	18413	79719447
Diarrhoea	120.52	40.62	238	6290	880251	78857609
Product taste abnormal	112.66	40.62	28	6500	2243	79735617
Flatulence	108.61	40.62	58	6470	42666	79695194
Inappropriate schedule of product administration	106.88	40.62	88	6440	133540	79604320
Gastric disorder	101.33	40.62	53	6475	37380	79700480
Abdominal pain upper	98.98	40.62	106	6422	223713	79514147
Cardiac failure congestive	82.26	40.62	78	6450	142324	79595536
Product colour issue	81.47	40.62	18	6510	862	79736998
Product solubility abnormal	79.69	40.62	18	6510	954	79736906
Hepatic steatosis	78.77	40.62	45	6483	37693	79700167
Product physical issue	61.71	40.62	20	6508	4165	79733695
No adverse event	53.59	40.62	35	6493	37157	79700703
Malaise	53.24	40.62	121	6407	489748	79248112
Treatment noncompliance	40.82	40.62	34	6494	52234	79685626

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AE09	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
FDA MoA	N0000178377	Potassium Ion Binding Activity
FDA EPC	N0000178378	Potassium Binder

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperkalemia	indication	14140009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	10485821	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8287847	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8475780	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8778324	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8889115	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	10485821	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8287847	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8475780	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8778324	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8889115	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	10485821	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8287847	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8475780	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8778324	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8889115	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	7556799	Feb. 27, 2025	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	7556799	Feb. 27, 2025	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	7556799	Feb. 27, 2025	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8216560	March 14, 2027	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8216560	March 14, 2027	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8216560	March 14, 2027	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8337824	May 29, 2030	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8337824	May 29, 2030	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8337824	May 29, 2030	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	11123363	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9492476	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9925212	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	11123363	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9492476	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9925212	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	11123363	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9492476	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9925212	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
7T97I3787N	UNII
D10149	KEGG_DRUG
1260643-52-4	SECONDARY_CAS_RN
4035186	VANDF
C4301626	UMLSCUI
CHEMBL2107840	ChEMBL_ID
CHEMBL2107875	ChEMBL_ID
9532	INN_ID
C568789	MESH_SUPPLEMENTAL_RECORD_UI
DB09263	DRUGBANK_ID
1716203	RXNORM
236636	MMSL
31246	MMSL
d08388	MMSL
016559	NDDF
016560	NDDF
715260008	SNOMEDCT_US
763550001	SNOMEDCT_US
1208912-84-8	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VELTASSA	HUMAN PRESCRIPTION DRUG LABEL	1	53436-084	POWDER, FOR SUSPENSION	8.40 g	ORAL	NDA	26 sections
VELTASSA	HUMAN PRESCRIPTION DRUG LABEL	1	53436-084	POWDER, FOR SUSPENSION	8.40 g	ORAL	NDA	26 sections
VELTASSA	HUMAN PRESCRIPTION DRUG LABEL	1	53436-168	POWDER, FOR SUSPENSION	16.80 g	ORAL	NDA	26 sections
VELTASSA	HUMAN PRESCRIPTION DRUG LABEL	1	53436-168	POWDER, FOR SUSPENSION	16.80 g	ORAL	NDA	26 sections
VELTASSA	HUMAN PRESCRIPTION DRUG LABEL	1	53436-252	POWDER, FOR SUSPENSION	25.20 g	ORAL	NDA	26 sections
VELTASSA	HUMAN PRESCRIPTION DRUG LABEL	1	53436-252	POWDER, FOR SUSPENSION	25.20 g	ORAL	NDA	26 sections